InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,191.20
(
-0.12%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.78
(
0.37%
)
Bitcoin
61,166.82
(
0.58%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: None

Monday, 02/04/2008 9:52:39 PM

Monday, February 04, 2008 9:52:39 PM

Post# of 4764
IMCL board member David Sidransky, M.D named to the Medical Advisory Board of
Rosetta Genomics.

http://biz.yahoo.com/prnews/080204/ukm035.html?.v=14

Also an interesting excerpt from a Rosetta press release regarding miRNA testing that they are developing (Dec 11, 2007).

“Differentiating squamous from non squamous lung cancer - As current targeted therapy for lung cancer can cause hemorrhaging in squamous cell lung cancer patients, differentiating between the cancer types is critical. Rosetta Genomics has identified several microRNA biomarkers that may allow for sensitive and specific identification of squamous cell carcinoma.”

Comments appreciated,

biophud
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up